NO20084599L - Sammensetninger, fremgangsmater og kit ved anvendelse av adenosin og inosin i kombinasjon for diagnose og behandling - Google Patents

Sammensetninger, fremgangsmater og kit ved anvendelse av adenosin og inosin i kombinasjon for diagnose og behandling

Info

Publication number
NO20084599L
NO20084599L NO20084599A NO20084599A NO20084599L NO 20084599 L NO20084599 L NO 20084599L NO 20084599 A NO20084599 A NO 20084599A NO 20084599 A NO20084599 A NO 20084599A NO 20084599 L NO20084599 L NO 20084599L
Authority
NO
Norway
Prior art keywords
inosine
adenosine
kits
diagnosis
compositions
Prior art date
Application number
NO20084599A
Other languages
English (en)
Norwegian (no)
Inventor
Philippe Gorny
Original Assignee
Adenobio Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adenobio Nv filed Critical Adenobio Nv
Publication of NO20084599L publication Critical patent/NO20084599L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20084599A 2006-03-31 2008-10-30 Sammensetninger, fremgangsmater og kit ved anvendelse av adenosin og inosin i kombinasjon for diagnose og behandling NO20084599L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78777106P 2006-03-31 2006-03-31
PCT/EP2007/002905 WO2007112986A1 (en) 2006-03-31 2007-03-30 Compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment

Publications (1)

Publication Number Publication Date
NO20084599L true NO20084599L (no) 2008-10-30

Family

ID=38197939

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084599A NO20084599L (no) 2006-03-31 2008-10-30 Sammensetninger, fremgangsmater og kit ved anvendelse av adenosin og inosin i kombinasjon for diagnose og behandling

Country Status (12)

Country Link
US (1) US20080056993A1 (ja)
EP (1) EP2004139A1 (ja)
JP (1) JP2009531367A (ja)
KR (1) KR20090010176A (ja)
CN (1) CN101453984A (ja)
AU (1) AU2007234006A1 (ja)
CA (1) CA2647770A1 (ja)
IL (1) IL194423A0 (ja)
NO (1) NO20084599L (ja)
RU (1) RU2008143202A (ja)
WO (1) WO2007112986A1 (ja)
ZA (1) ZA200808368B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
HU227743B1 (en) 2011-07-22 2012-02-28 Debreceni Egyetem Eardrop composition and process for producing this
AU2014224599B2 (en) 2013-03-08 2018-11-08 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231086A (en) * 1985-09-24 1993-07-27 Item Development Aktiebolag Continuous administration adenosine to increase myocardial blood flow
DE3701497A1 (de) * 1987-01-20 1988-07-28 Frankhof Wolfgang Arzneimittel, enthaltend lokalanaesthetika und nukleoside sowie dessen verwendung zur behandlung von muskelverletzungen
US5070877A (en) * 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
US5187162A (en) * 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US6180616B1 (en) * 1990-05-10 2001-01-30 Atsuo F. Fukunaga Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
US5236908A (en) * 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
AU6516494A (en) * 1993-04-15 1994-11-08 New York University Adenosine receptor agonists for the promotion of wound healing
SE9301324D0 (sv) * 1993-04-21 1993-04-21 Item Development Ab New method of treatment
US6342484B1 (en) * 1993-06-30 2002-01-29 Board Of Regents, The University Of Texas Systems Method and compositions for promotion of wound treatment
US5852000A (en) * 1993-08-25 1998-12-22 Otsuka Pharmaceutical Factory, Inc. Cardiac rehabilitation agent
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
SE9401499D0 (sv) * 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
US5629298A (en) * 1995-03-13 1997-05-13 University Of Massachusetts Medical Center Adenosine as a positive inotrop in the compromised heart
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
US6316423B1 (en) * 1996-04-10 2001-11-13 The United States Of America As Represented By The Departmant Of Health And Human Services Method of treating ischemic, hypoxic and anoxic brain damage
US5873366A (en) * 1996-11-07 1999-02-23 Chim; Nicholas Method for transmyocardial revascularization
US6211165B1 (en) * 1997-05-09 2001-04-03 The Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
US6329349B1 (en) * 1997-10-23 2001-12-11 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
TR200103235T2 (tr) * 1999-03-23 2002-01-21 James Cook University Organ tutma, koruma ve saklama.
US6103702A (en) * 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
US6492103B1 (en) * 2000-01-31 2002-12-10 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
US6566371B2 (en) * 2000-04-28 2003-05-20 University Of Pittsburgh Intraperitoneal administration of adenosine for the treatment of prevention of gastrointestinal of systemic diseases
US6599283B1 (en) * 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
US7923032B2 (en) * 2002-11-26 2011-04-12 Seacoast Neuroscience, Inc. Buoyant polymer particles for delivery of therapeutic agents to the central nervous system

Also Published As

Publication number Publication date
WO2007112986A1 (en) 2007-10-11
AU2007234006A1 (en) 2007-10-11
ZA200808368B (en) 2009-12-30
CN101453984A (zh) 2009-06-10
EP2004139A1 (en) 2008-12-24
IL194423A0 (en) 2009-08-03
JP2009531367A (ja) 2009-09-03
CA2647770A1 (en) 2007-10-11
KR20090010176A (ko) 2009-01-29
US20080056993A1 (en) 2008-03-06
RU2008143202A (ru) 2010-05-10

Similar Documents

Publication Publication Date Title
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
NO20081127L (no) Vaksinering mot Dengue virusinfeksjon
TW200738263A (en) ANG2 and VEGF inhibitor combinations
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
ATE534752T1 (de) Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
EA201101520A1 (ru) Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
UA101944C2 (ru) Композиции и способы применения для антител dickopf-1
GB0521521D0 (en) Diagnostic methods and kits
NO20092637L (no) Fremgangsmater for behandling
WO2007047408A3 (en) Promac signature application
MY160041A (en) Compositions and methods for treating parasitic infections
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
WO2008024473A3 (en) Mapping of genomic interactions
ZA200709011B (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
CR10667A (es) Compositions and methods for diagnosing and treating cancer
EA201001322A1 (ru) Вакцины против хламидиоза
EA201270325A1 (ru) Способы лечения саркомы с использованием эпиметаболической сдвигающей добавки (кофермента q10)
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
WO2007149982A3 (en) Diagnosis of autoimmune disease
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
WO2007014318A3 (en) Zebrafish models of acute myelogenous leukemia
EP2035015A4 (en) COMPOSITIONS, METHODS AND KITS FOR DRY EYE TREATMENT
WO2006091861A8 (en) Compositions and methods relating to cns lymphoma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application